AzTrials
AzTrials

Ischemic StrokePhase 1RICE PACNCT03152799

Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study

A Phase 1 study testing RIPC Remote Ischaemic Pre-Conditioning in people with Ischemic Stroke, run by University College, London.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Ischaemic stroke causes significant morbidity and mortality and is a leading cause of disability within an ageing United Kingdom (UK) population. Proximal anterior circulation occlusion is associated with a particularly poor prognosis, but its management has undergone a paradigm shift following clinical introduction… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ischemic Stroke
What is being tested?
RIPC Remote Ischaemic Pre-Conditioning
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
No sites listed yet
Study dates
1 Aug 2017to 31 Dec 2019
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Acute, symptomatic proximal anterior circulation occlusion
  • able to commence remote ischaemic conditioning within 6h of symptom onset
  • identified as candidate for endovascular intervention according to local criteria

Who cannot join

  • Age < 18 years
  • Coagulopathy; International Normalised Ratio (INR) >2, alteplase dose > 90mg or 0.9mg/kg; platelet count < 50 x 10^9/L
  • pregnancy
  • BP >= 185/110 despite therapeutic intervention
  • medical illness which interferes with outcome assessments (disability from other neurological disease)
  • dependent on others for activities of daily living (ADLs) prior to current stroke (mRS modified Rankin Score was 3 - 5).
Show all 9Show fewer
  • unlikely to be able to participate in study follow-up procedures (lives > 100 miles away; no fixed abode)
  • already enrolled in another clinical trial involving investigational medicinal product or device
  • baseline scan demonstrating significant prior infarction in the affected Middle Cerebral Artery (MCA) territory or an infarct that exceeds > 1/3 MCA territory

Trial locations and contacts

No sites are listed yet.

Richard Perry, PhD MRCP contact

020 3448 3416

richard.perry@uclh.nhs.uk

Robert Simister, PhD MRCP contact

020 3448 3416

robert.simister@uclh.nhs.uk

About this study

Official title: Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion (RICE PAC) Study

Ischaemic stroke causes significant morbidity and mortality and is a leading cause of disability within an ageing United Kingdom (UK) population. Proximal anterior circulation occlusion is associated with a particularly poor prognosis, but its management has undergone a paradigm shift following clinical introduction of endovascular recanalization, establishing rapid reperfusion of the ischaemic penumbra.

Remote ischaemic conditioning (RIC) is highly effective at attenuating cerebral infarction in basic research studies and has the potential to further improve patient outcome if used as an adjunct to invasive revascularisation strategies. We aim to trial remote ischaemic conditioning at the time of revascularisation, and then daily for the duration of the seven-day in-patient stay, compared to a sham conditioning procedure. This pilot, single-centre study will determine efficacy/ tolerability of RIC to reduce cerebral infarction (primary endpoint: determined by brain magnetic resonance imaging [MRI]) and improve functional status (secondary end-points: National Institutes of Health Stroke Severity (NIHSS); European Quality of Life questionnaire EurQoL), with the data providing the necessary parameters for power calculations and leveraging charitable funding for a subsequent multi-centre study.

Read the detailed description

The aims of our study are to:

  1. Demonstrate safety of remote ischaemic conditioning (RIC) in stroke patients;
  2. Demonstrate practicality of the intervention (RIC);
  3. Demonstrate the practicality of the study protocol and imaging modalities;
  4. Determining appropriate and measurable end-points: e.g. cerebral infarct reduction (MRI), reduction of cerebral oedema, functional assessment and quality of life survey;
  5. Provide preliminary data on likely effect size of the RIC intervention versus the sham procedure.

Background and Rationale:

Acute ischaemic stroke represents a significant cause of morbidity and mortality in the UK. It is estimated that 110,000 strokes occur in England each year, with an incidence of between 1-36/1000/year. Patients presenting with a proximal vessel occlusion in the anterior circulation have a particularly poor prognosis, with approximately 20% 90-day mortality and significant morbidity despite thrombolysis. Recently, endovascular recanalization with mechanical thrombectomy trials have brought about a paradigm shift in the optimal management of this high-risk group of patients; the interventional extraction of the occluding thrombus demonstrating significant benefits in MR-CLEAN(3), ESCAPE, EXTEND-IA (intra-arterial), SWIFT PRIME and REVASCAT (revascularisation) studies. Echoing primary percutaneous intervention in the management of ST-elevation myocardial infarction, endovascular recanalization represents rapid restoration of blood flow to the ischaemic cerebrum - with the promise of improved neurological salvage and functional outcome.

Reperfusion Injury:

Reperfusion is not, however, a benign process. Demonstrable in many organ systems including the brain (but studied most extensively in the heart), reperfusion leads to rapid restoration of intracellular pH, mitochondrial calcium overload and generation of reactive oxygen species - conditions that are prime for the opening of the mitochondrial permeability transition pore (mPTP). The mPTP, a large capacitance pore that forms on the inner mitochondrial membrane, leads to mitochondrial disruption and the release of proteins that trigger cell death. Therefore modifying conditions of reperfusion/ triggering cellular protection pathways are the key targets for optimising tissue salvage associated with reperfusion following any acute revascularisation intervention.

Remote ischaemic conditioning:

The brain has been demonstrated to share many of the cytoprotective signalling pathways found in other organs such as the heart, and like the heart, can be protected by ischaemic conditioning(6). Ischaemic conditioning can be either applied either directly to the organ, or more conveniently to a remote tissue (such as an arm, through inflation of a blood pressure cuff), either prior to, during or immediately following the restoration of blood flow to the ischaemic tissue (pre-, peri- and post-conditioning respectively). The remote conditioning stimulus leads to the activation of cellular survival kinases (termed the reperfusion injury salvage kinase (RISK) cascade) that in turn leads to inhibition of mPTP opening, and thus cell survival.

Ischaemic conditioning and neuro-protection:

While the phenomenon of ischaemic conditioning was first described and best characterised in the heart, it is well recognised that the ischaemic conditioning can result in cytoprotection across many mammalian organs, including the brain. Indeed, contemporaneous with the seminal myocardial preconditioning paper by Reimer, Murray and Jennings in the dog, Schurr et al demonstrated ischaemic preconditioning could also protect adult rat hippocampal slices against injurious anoxia/re-oxygenation. Ischaemic conditioning of neuronal tissue has subsequently been demonstrated to be triggered and mediated by similar receptor and downstream signalling pathways (e.g. G-protein coupled receptors, RISK pathway activation and suppression of cell death pathways), and that remote ischaemic conditioning is also effective at significantly attenuating the volume of cerebral necrosis in rat experimental models of acute right middle cerebral artery occlusion stroke (typically reducing infarct size by 40-60%). Similar results are observed in mouse (middle cerebral embolization, followed by thrombolysis with tissue-plasminogen activator) and in piglet, where the injurious effects of hypothermic circulatory arrest were attenuated, improving both functional and histological outcomes.

With building evidence of efficacy against cerebral ischaemia/reperfusion injury in the pre-clinical basic science studies, there is enthusiasm to translate these encouraging data into an effective clinical strategy for the management of acute stroke in man. A recent prospective, open-label, blinded outcome proof-of-concept study in Danish patients undertook ischaemic per-conditioning in patients presenting with an acute stroke syndrome. With the conditioning stimulus performed in the ambulance, the ischaemic stroke diagnosis was made/confirmed later in hospital. In patients with confirmed ischaemic stroke, they found patients in the intervention arm had a better functional status by National Institutes of Health Stroke Scale score on admission and an overall smaller infarct, but the study was overall neutral on the pre-specified primary endpoint (penumbral salvage, defined as the volume of the perfusion-diffusion mismatch not progressing to infarction after 1 month). There are useful lessons and observations to be made regarding the design of this trial that influences the design of the trial proposed within this application. First, thrombolysis does not guarantee re-canalisation of the culprit artery, and where restoration of blood flow does occur, the time of onset of reperfusion may be unpredictable. Thus, restoration of blood flow may either not have occurred, or when it had, may have occurred outside the protective time-frame of the remote ischaemic conditioning stimulus (classical conditioning has a protective "window" of typically just 2-3 hours).

Therefore, we are seeking to combine ischaemic conditioning with an effective endovascular re-canalisation procedure where the success and time of reperfusion are known. Second, in the Danish study, there would have been significant heterogeneity in aetiology of the presenting stroke symptoms that will include both anterior and posterior circulation occlusion and also small vessel disease. The pre-clinical efficacy of remote ischaemic conditioning is predominantly with models of anterior circulation occlusion and therefore, we have made this cohort of patients the focus of our study. And finally, there is emerging evidence that in order to ensure persistent infarct size reduction, it is critical to combine both initial ischaemic per-conditioning and subsequent post-conditioning to tackle both the acute reperfusion injury (the first 15 minutes of reperfusion) and the subsequent second phase of reperfusion injury (that occurs in the following hours and days). Thus our study is designed to combine both ischaemic per-conditioning and repeated post-conditioning over the following seven days to harvest the benefit of both conditioning strategies.

Interestingly, a Chinese study (RIC to both arms daily for 300 days after the initial stroke) was shown to be safe and effective. While this study had a different outcome to ours (attenuating the rate of stroke recurrence following the initial presentation), the efficacy of the RIC intervention nonetheless provides further encouragement that RIC may be an effective intervention in this group of patients.

In summary therefore, we are seeking to combine ischaemic conditioning with an effective endovascular re-canalisation procedure where the success and time of reperfusion are known, in a vascular territory that is known to benefit from RIC and are looking to combine both ischaemic per-conditioning and repeated post-conditioning over the following seven days to harvest the benefit of both conditioning strategies upon acute and inflammatory phases of reperfusion injury - encompassing the period over which peak cerebral oedema is typically observed.

Conditions
Ischemic Stroke
Being tested
RIPC Remote Ischaemic Pre-Conditioning, Sham Control
Keywords
remote ischaemic conditioning, remote ischemic conditioning, cerebral infarction, ischaemia reperfusion injury, ischemia reperfusion injury, anterior circulation stroke, mechanical thrombectomy
Medical subject headings
Ischemic Stroke, Cerebral Infarction, Reperfusion Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RIPC Remote Ischaemic Pre-ConditioningProcedure or surgery

    Also called Remote Ischaemic PreConditioning

    intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation

  • Sham ControlOther

    intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response

Study groups in NCT03152799
Study groupRoleWhat they receive
Remote Ischaemic Pre-Conditioning (RIPC) InterventionExperimentalRemote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
Receives: Procedure: RIPC Remote Ischaemic Pre-Conditioning
Sham ControlSham comparatorSham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
Receives: Other: Sham Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. reduction of infarct size as proportion of ischaemic penumbra following revascularisation

    Proportion of ischaemic penumbra determined by MRI at 3 months post-revascularisation

    Measured: 3 months after revascularisation / thrombectomy

Secondary outcomes (4)
  1. Reduction of cerebral oedema and infarct size (second-phase reperfusion injury)

    Proportion of ischaemic penumbra comparing MRI data at 24 hours and 7 days post-thrombectomy

    Measured: MRI at 7 days post-thrombectomy

  2. Neurological Recovery at 24 h and 3 months post-revascularisation

    modified Rankin Score

    Measured: at 24h hours and 3 months post-revascularisation

  3. Neurological Recovery at 24 h and 3 months post-revascularisation

    NIHSS (National Institutes of Health Stroke Scale)

    Measured: at 24h hours and 3 months post-revascularisation

  4. Neurological Recovery at 24 h and 3 months post-revascularisation

    QoL (Quality of Life) assessment

    Measured: at 24h hours and 3 months post-revascularisation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2017
  2. Study start1 Aug 2017 (estimated)
  3. Primary completion1 Aug 2019 (estimated)
  4. Study completion31 Dec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Model description
pilot, single-centre, double-blind, sham-controlled (non-clinical trial of investigational medicinal product \[non-CTIMP\]) study of repeated daily remote ischaemic conditioning vs placebo/sham in the context of acute anterior circulation stroke
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03152799
Sponsor's protocol ID
222254
Acronym
RICE PAC
Status last verified
May 2017
First submitted
8 Mar 2017
Last updated
15 May 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Department of Health: Progress in Improving Stroke Care. In: Office NA, editor.: The Stationary Office; 2010.

  • Hippisley-Cox J, Pringle M, Ryan R. Stroke: Prevalence, Incidence and Care in General Practices 2002-2004. Final Report to the National Stroke Audit Team. In: Physicians RCo, editor. 2004.

  • Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ, van Walderveen MA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama a Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle LJ, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Majoie CB, Dippel DW; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. doi: 10.1056/NEJMoa1411587. Epub 2014 Dec 17.

    PubMed 25517348
  • Moore JM, Griessenauer CJ, Gupta R, Adeeb N, Patel AS, Ogilvy CS, Thomas AJ. Landmark papers in cerebrovascular neurosurgery 2015. Clin Neurol Neurosurg. 2016 Sep;148:22-8. doi: 10.1016/j.clineuro.2016.06.007. Epub 2016 Jun 18.

    PubMed 27366977
  • Bell RM, Yellon DM. There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury. Cardiovasc Ther. 2011 Dec;29(6):e67-79. doi: 10.1111/j.1755-5922.2010.00190.x. Epub 2010 Jul 14.

    PubMed 20645988
  • Hahn CD, Manlhiot C, Schmidt MR, Nielsen TT, Redington AN. Remote ischemic per-conditioning: a novel therapy for acute stroke? Stroke. 2011 Oct;42(10):2960-2. doi: 10.1161/STROKEAHA.111.622340. Epub 2011 Aug 11.

    PubMed 21836089
  • Hougaard KD, Hjort N, Zeidler D, Sorensen L, Norgaard A, Hansen TM, von Weitzel-Mudersbach P, Simonsen CZ, Damgaard D, Gottrup H, Svendsen K, Rasmussen PV, Ribe LR, Mikkelsen IK, Nagenthiraja K, Cho TH, Redington AN, Botker HE, Ostergaard L, Mouridsen K, Andersen G. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke. 2014 Jan;45(1):159-67. doi: 10.1161/STROKEAHA.113.001346. Epub 2013 Nov 7.

    PubMed 24203849
  • Ren C, Wang P, Wang B, Li N, Li W, Zhang C, Jin K, Ji X. Limb remote ischemic per-conditioning in combination with post-conditioning reduces brain damage and promotes neuroglobin expression in the rat brain after ischemic stroke. Restor Neurol Neurosci. 2015;33(3):369-79. doi: 10.3233/RNN-140413.

    PubMed 25868435
  • Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, Jia J, Hua Y, Wang X, Ding Y, Lo EH, Ji X. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012 Oct 30;79(18):1853-61. doi: 10.1212/WNL.0b013e318271f76a. Epub 2012 Oct 3.

    PubMed 23035060

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing RIPC Remote Ischaemic Pre-Conditioning in people with Ischemic Stroke, run by University College, London.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 May 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Richard Perry, PhD MRCP (020 3448 3416, richard.perry@uclh.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

reduction of infarct size as proportion of ischaemic penumbra following revascularisation (time frame: 3 months after revascularisation / thrombectomy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03152799, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in